EUVIMEDEUVIMED entdecken
Crossref

Adjuvant Chemotherapy Duration and Disease-Free Survival in Low-Risk Stage III Colon Cancer with N1a-b and N1c Disease: Insights from a Single-Center Retrospective Analysis

Beliz Bahar Karaoğlan, İremsu Öztürk, Cihangir Akyol, Berna Savaş, Güngör Utkan

Journal of Gastrointestinal Cancer · 2025

DOI: 10.1007/s12029-024-01135-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal Cancer, 2025. Verfasst von Beliz Bahar Karaoğlan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Medical Oncology, Ankara University, Ankara, Türkiye. bbaharulas@gmail.com. Hauptthemen laut MEDLINE: Colonic Neoplasms, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tumor deposits (TDs) are known to have a poor prognosis independent of lymph node (LN) involvement and are considered equivalent to LN metastases in the latest staging system. In stage III colon cancer (CC), high-risk patients (pT4 or pN2) receive 6 months of adjuvant chemotherapy, while low-risk patients (pT1-3 and N1) are recommended either 3 or 6 months of CAPOX or 6 months of FOLFOX therapy. However, the optimal chemotherapy duration for low-risk patients classified as pN1c remains unknown. The aim of this study is to investigate the impact of adjuvant chemotherapy duration (3 months vs. 6 months) on survival in patients with low-risk stage III CC either in pN1a-b and pN1c patient groups. METHODS: We retrospectively analyzed patients with stage III CC who underwent surgery at a tertiary center between January 2014 and May 2024. Demographic and pathological data of patients were retrospectively collected. The primary outcome was disease-free survival (DFS). RESULTS: A total of 142 patients were included. Among the patients, 116 were pT1-3N1a-b and 26 were pT1-3N1c. Local (23.1% vs. 1.7%, P < 0.001) and overall (38.5% vs 14.6%, P = 0.011) recurrences were significantly higher in the pN1c group. Univariate and multivariate analyses revealed no significant impact of adjuvant chemotherapy duration on DFS in the pN1a-b group (P = 0.359), whereas in the pN1c group, 3-month chemotherapy resulted in significantly shorter DFS (P = 0.044) in univariate analysis. CONCLUSION: Our study indicates that shorter duration of adjuvant chemotherapy is associated with worse survival and 6-month chemotherapy is recommended for patients with pT1-3 and N1c disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsNeoplasm StagingAntineoplastic Combined Chemotherapy ProtocolsHumansChemotherapy, AdjuvantFemaleRetrospective StudiesMaleMiddle AgedAgedDisease-Free SurvivalFluorouracilLeucovorinAdultPrognosisOrganoplatinum Compounds

Stichwörter der Autor:innen

AdjuvantChemotherapyColon cancerTumor deposit

Substanzen

FluorouracilLeucovorinOrganoplatinum Compounds

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Medical Oncology, Ankara University, Ankara, Türkiye. bbaharulas@gmail.com.
  • Faculty of Medicine, Department of Medical Oncology, Ankara University, Ankara, Türkiye.
  • Faculty of Medicine, Department of Surgery, Ankara University, Ankara, Türkiye.
  • Faculty of Medicine, Department of Pathology, Ankara University, Ankara, Türkiye.

Zitieren

APA

Karaoğlan, B. B., Öztürk, İ., Akyol, C., Savaş, B., & Utkan, G. (2025). Adjuvant Chemotherapy Duration and Disease-Free Survival in Low-Risk Stage III Colon Cancer with N1a-b and N1c Disease: Insights from a Single-Center Retrospective Analysis. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-024-01135-2

Vancouver

Karaoğlan BB, Öztürk İ, Akyol C, Savaş B, Utkan G. Adjuvant Chemotherapy Duration and Disease-Free Survival in Low-Risk Stage III Colon Cancer with N1a-b and N1c Disease: Insights from a Single-Center Retrospective Analysis. Journal of Gastrointestinal Cancer. 2025. doi:10.1007/s12029-024-01135-2

BibTeX
@article{Karaolan2025,
  author = {Karaoğlan, Beliz Bahar and Öztürk, İremsu and Akyol, Cihangir and Savaş, Berna and Utkan, Güngör},
  title = {Adjuvant Chemotherapy Duration and Disease-Free Survival in Low-Risk Stage III Colon Cancer with N1a-b and N1c Disease: Insights from a Single-Center Retrospective Analysis},
  journal = {Journal of Gastrointestinal Cancer},
  year = {2025},
  doi = {10.1007/s12029-024-01135-2}
}
Kostenlos starten →